<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03394950</url>
  </required_header>
  <id_info>
    <org_study_id>k201731</org_study_id>
    <nct_id>NCT03394950</nct_id>
  </id_info>
  <brief_title>Butyphthalide in Combination With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke</brief_title>
  <official_title>Butyphthalide in Combination With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke (BRAIS)：a Pilot, Prospective, Random, and Double Blinded Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hui-Sheng Chen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute ischemic stroke (AIS) is the most common type of stroke, which has high rate of&#xD;
      morbidity, mortality and disability. A large number of studies have confirmed that the&#xD;
      thrombolytic therapy can effectively open blood vessels and improve the functional prognosis&#xD;
      of acute ischemic stroke. Therefore, all guidelines recommend giving thrombolysis treatment&#xD;
      to acute ischemic stroke patients within 4.5 hours of onset. However, about 1/3 patients&#xD;
      receiving thrombolysis will have good prognosis, while a large number of patients will still&#xD;
      be disabled and even dead. How to improve the neurofunctional prognosis of thrombolytic&#xD;
      patients has been a hot topic in the world.&#xD;
&#xD;
      Butyl phthalide is type I chemical drugs. Some multicenter randomized, double-blind,&#xD;
      placebo-controlled clinical trials have showed that acute ischemic stroke patients taking&#xD;
      butyl phthalide has better lateral branch circulation and living ability score than patients&#xD;
      taking placebo. Besides, butyl phthalide treatment is safe. The animal experiment indicated&#xD;
      that buphthalein could significantly improve secondary side branch circulation, recover the&#xD;
      microarterial diameter of the soft meninges in the ischemic region and increase the blood&#xD;
      flow rate.&#xD;
&#xD;
      Based on the discussion, we assume that: giving butyl phthalide to patients with acute&#xD;
      ischemic stroke in advance, might promote and improve the formation of collateral circulation&#xD;
      to freeze ischemia penumbra. Based on this hypothesis, we would like to explore the efficacy&#xD;
      and safety of butyl phthalide combined with rtPA thrombolysis in the treatment of acute&#xD;
      ischemic stroke.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 25, 2018</start_date>
  <completion_date type="Actual">May 29, 2021</completion_date>
  <primary_completion_date type="Actual">May 29, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of mRS score (0-2) (90 days)</measure>
    <time_frame>90 days</time_frame>
    <description>Percentage of mRS score (0-2) at 90 days</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Stroke, Ischemic</condition>
  <arm_group>
    <arm_group_label>rtPA combined with Butyphthalide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous treatment with 25mg butyphthalide, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with 25mg butyphthalide 2 times/day for 14 days, followed by oral butyphthalide capsule (0.2g 3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rtPA compared with placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous treatment with placebo injection, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with placebo injection 2 times/day for 14 days, followed by oral placebo capsule (3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Butyphthalide combined with rtPA</intervention_name>
    <description>Intravenous treatment with 25mg butyphthalide, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with 25mg butyphthalide 2 times/day for 14 days, followed by oral butyphthalide capsule (0.2g 3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.</description>
    <arm_group_label>rtPA combined with Butyphthalide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rtPA</intervention_name>
    <description>Intravenous thrombolysi with 0.9mg/kg rtPA, followed by other treatments according to guidelines</description>
    <arm_group_label>rtPA compared with placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;18 years;&#xD;
&#xD;
          2. Diagnosis of anterior circulation infarct;&#xD;
&#xD;
          3. First stroke onset or past stroke without obvious neurological deficit (mRS≤1);&#xD;
&#xD;
          4. Time from onset to treatment ≤4.5 hours;&#xD;
&#xD;
          5. SBP/DBP ≤ 180/110mmHg;&#xD;
&#xD;
          6. No hemorrhagic imaging changes showed in CT;&#xD;
&#xD;
          7. Signed informed consent by patient self or legally authorized representatives.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of stroke within 3 months;&#xD;
&#xD;
          2. History of intracranial hemorrhage;&#xD;
&#xD;
          3. Suspected subarachnoid hemorrhage;&#xD;
&#xD;
          4. Intracranial tumour, vascular malformation or arterial aneurysm;&#xD;
&#xD;
          5. Major surgery within 1 month;&#xD;
&#xD;
          6. Systolic pressure ≥180 mmHg or diastolic pressure ≥110 mmHg;&#xD;
&#xD;
          7. Platelet count &lt; 100×109／L;&#xD;
&#xD;
          8. Heparin therapy or oral anticoagulation therapy within 48 hours;&#xD;
&#xD;
          9. Severe disease with a life expectancy of less than 3 months;&#xD;
&#xD;
         10. Blood glucose &lt; 50 mg/dL (2.7mmol/L);&#xD;
&#xD;
         11. Patients who have received any other investigational drug or device within 3 months;&#xD;
&#xD;
         12. Researchers consider patients inappropriate to participate in the registry. -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>chen huisheng, doctor</last_name>
    <role>Study Director</role>
    <affiliation>General Hospital of Shenyang Military Region</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Hospital of ShenYang Military Region</name>
      <address>
        <city>ShenYang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 3, 2018</study_first_submitted>
  <study_first_submitted_qc>January 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2018</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Hui-Sheng Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>thrombolysis</keyword>
  <keyword>Butyphthalide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

